Evidence map›Paper›PMID 42440745›Full record

ArticleMedComm2026

Chemoimmunotherapy Combined With Antiangiogenic Therapy in Advanced Triple-Negative Breast Cancer: Real-World Outcomes From a Retrospective Cohort Study.

Yudong Li, Jinna Lin, Mengdi Zhu, Zijie Cai, Liang Jin, Shunying Li, Qianfeng Shi, Hongna Lai, Chang Gong, Qiang Liu

Abstract read
In one paragraph

Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yudong LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Jinna LinGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.ORCID https://orcid.org/0009-0002-0817-5238
Mengdi ZhuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Zijie CaiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Liang JinGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Shunying LiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Qianfeng ShiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Hongna LaiGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Chang GongGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.
Qiang LiuGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital Sun Yat-Sen University Guangzhou China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) has a poor prognosis and limited treatment options. Although programmed death protein 1 (PD-1) inhibitor-based chemotherapy and its combination with antiangiogenic agents are increasingly used clinically, comparative effectiveness data are lacking. This real-world study compared chemoimmunotherapy (IC) versus chemoimmunotherapy plus antiangiogenic therapy (ICA) in advanced TNBC. Among 218 eligible patients, the ICA group (

Indexed as

advanced breast cancerantiangiogenic therapyimmune checkpoint inhibitorimmunotherapytriple‐negative breast cancer

Identifiers

PMID42440745
PMCPMC13334144

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.